Table 6.
Druggable targets.
| Target | Intervention | In Vitro Data | Case Reports/Studies | References |
|---|---|---|---|---|
| Crosstalk between YAP1 and Wnt/beta-catenin | Hippo/YAP1 signaling inhibition | yes | none | Abduch et al., 2016 [23] |
| PDL1 expression | Checkpoint inhibition | yes | case reports/several trials | Altieri, 2020, Geoerger, 2020 [131,132] |
| Overexpression of Aurora kinases A | Aurora kinase inhibition | yes | none | Borges, 2013 [26] |
| CDK1, CCNB1, CDC20, and BUB1B | yes | none | Fragoso, 2012; Kulshrestha, 2016 [133,134] | |
| HMGCR-overexpressing tumors | Lovastatin | yes | none | Lin, 2010 [123] |
| Overexpression of IGF1R | IGF1R inhibition | yes | phase ½ | Lira, 2016; Jones, 2015; Weigel, 2014 [33,135,136] |
| Overexpression of VEGFR | VEGFR inhibition/tyrosine kinase inhibition | yes | case reports/several trials | Pianovski, 2013, Altieri, 2020 [131,137] |
| mTOR kinase activity | mTOR inhibition | yes | case reports/several trials | Pianovski, 2013, Altieri, 2020 |
| ATRX | yes | none | Pinto, 2015 [111,131,137] | |
| ZNRF3 | yes | none | Pinto, 2015 [111] |